On May 6, 2019, Lieff Cabraser partner Rachel Geman was appointed to the Plaintiffs’ Economic Reimbursement Steering Committee in the national consumer fraud Valsartan contamination litigation in federal court in New Jersey, In Re: Valsartan Products Liability Litigation, MDL No. 2875.
Huge amounts of the hypertension drug Valsartan, the generic equivalent of the hypertension drug Diovan, were contaminated with a carcinogen called NDMA. In the wake of the Valsartan contamination and ensuing drug recall, lawsuits were filed across the United States on behalf of patients who purchased the unsafe contaminated drug, including for fraud and violation of warranties as well as other laws relating to the safe sale and distribution of prescription drugs. These lawsuits have been aggregated into a single multidistrict litigation in U.S. District Court in New Jersey.
Learn more about the Valsartan consumer fraud litigation.